Truist reiterates Hold on Hims and Hers stock, $32 target
Truist reiterated a Hold rating on Hims and Hers (HIMS) with a $32 price target, citing proprietary card data showing a 16% decline in GLP-1 billings in September. The stock trades at $29.54, with InvestingPro suggesting it may be overvalued. KeyBanc maintained a Sector Weight rating, noting AI-driven healthcare improvements. The company faces challenges from Visa's Acquirer Monitoring Program due to credit card disputes.
How this was made
The 30-second read
Why it matters
Analyst coverage reinforces current valuation levels while flagging cost pressures from credit‑card disputes.
Market read
The reiteration of a Hold rating with a modest price target provides limited trading impetus, but the disclosed dispute surcharge adds a risk factor.
What to watch
Potential regulatory scrutiny of GLP‑1 marketing and the impact of AI initiatives on long‑term margins.
Background
Truist and KeyBanc provided analyst coverage, noting AI usage and recent product launches in Australia.
Ticker impact
Truist reiterated a Hold rating on Hims & Hers with a $32 price target, citing recent GLP‑1 billing trends and a Visa dispute surcharge.
potential modest upside as the market prices in the $32 target versus current $29.5 price.
Hold rating with a target above current price implies limited upside; dispute surcharge may cap gains.
Market effects
Highlights ongoing volatility in the GLP‑1 weight‑loss segment, may affect peer valuations.
U.S. health‑tech sector sees mixed sentiment due to dispute surcharge.
Limited; primarily impacts Hims & Hers and its immediate peers.
Counterpoint
The Visa surcharge could outweigh the modest upside from the price target, suggesting a potential downside.
Key entities
- analystTruist Securities
Issued Hold rating and $32 price target.
- analystKeyBanc
Maintained Sector Weight rating, highlighted AI investments.
